Thus, we thought that inhibition of HMGB1 might contribute in-vivo in-vitro to the therapeutic effect of taxifolin in cardiovascular disease, and the present study also demonstrates the possible mechanism underlying these effects using in-vivo and in-vitro experiments using multiple methods might be a novel therapeutic strategy for cardiovascular disease. The gene discussed is HMGB1; the disease is cardiovascular disorder.